Somewhat Favorable Press Coverage Somewhat Unlikely to Affect AEterna Zentaris (AEZS) Stock Price

Media headlines about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AEterna Zentaris earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 43.3769451824791 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Several research firms have commented on AEZS. ValuEngine lowered AEterna Zentaris from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Zacks Investment Research lowered AEterna Zentaris from a “buy” rating to a “hold” rating in a research report on Monday, January 29th. Maxim Group set a $4.00 price objective on AEterna Zentaris and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a “buy” rating in a research report on Wednesday, November 29th.

Shares of AEterna Zentaris (NASDAQ AEZS) remained flat at $$1.65 during trading hours on Tuesday. 58,673 shares of the company traded hands, compared to its average volume of 506,142. AEterna Zentaris has a fifty-two week low of $0.78 and a fifty-two week high of $3.75. The stock has a market cap of $27.78, a PE ratio of -0.91 and a beta of 0.71.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-aeterna-zentaris-aezs-stock-price.html.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency.

Insider Buying and Selling by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply